Cardiometabolic HIIT-RT Study

October 10, 2018 updated by: Universidad Santo Tomas

High Intensity Interval- vs Resistance or Combined- Training for Improving Cardiometabolic Health in Overweight Adults (Cardiometabolic HIIT-RT Study): Study Protocol for a Factorial Randomised Controlled Trial

Several studies have shown relationship between exercise intensity and improvement cardiometabolic health such as body composition, endothelial function, blood pressure and blood lipids. It has been suggested that high intensity interval training and also strength or resistance training generate positive effects on metabolic risk factors, nevertheless the comparison between both types of training and their combination has not yet provided conclusive evidence. Also, it has been shown that dietary restriction has similar or more positive effects that exercise alone and the effect is greater when it is combined with exercise. For these reasons, it is necessary to clarify which type of training, in combination with a dietary restriction, is more effective to improve cardiometabolic health

Study Overview

Detailed Description

The investigators hypothesized that high intensity interval, resistance training or combined training would result in similar improvements in cardiometabolic health as compared to the usual clinical care in a cohort of sedentary overweight (age 30-50 years old).

Study Type

Interventional

Enrollment (Actual)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Cundinamarca
      • Bogotá, Cundinamarca, Colombia
        • Robinson Ramírez Vélez Ph.D

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

30 years to 50 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Meets at least one criteria for metabolic Syndrome (IDF 2006): Central obesity: waist circumference ≥90cm (men) ≥80cm (women); triglycerides ≥ 150mg/dl; HDL-c <40mg/dl (men) <50 (women); Blood pressure ≥130/85mmHg and fasting plasma glucose ≥ 100mg/dL.
  • Written informed consent.
  • Interested in improving health and fitness.

Exclusion Criteria:

  • Systemic infections.
  • Weight loss or gain of >10% of body weight in the past 6 months for any reason.
  • Currently taking medication that suppresses or stimulates appetite.
  • Uncontrolled hypertension: systolic blood pressure 160 mm Hg or diastolic blood pressure 95 mm Hg on treatment.
  • Gastrointestinal disease, including self-reported chronic hepatitis or cirrhosis, any episode of alcoholic hepatitis or alcoholic pancreatitis within past year, inflammatory bowel disease requiring treatment in the past year, recent or significant abdominal surgery (e.g., gastrectomy).
  • Asthma.
  • Diagnosed diabetes (type 1 or 2), fasting impaired glucose tolerance (blood glucose 118 mg/dL), or use of any anti-diabetic medications.
  • Currently taking antidepressant, steroid, or thyroid medication, unless dosage is stable (no change for 6 months).
  • Any active use of illegal or illicit drugs.
  • Current exerciser (>30 min organized exercise per week).
  • Indication of unsuitability of current health for exercise protocol (PARQ).
  • Any other conditions which, in opinion of the investigators, would adversely affect the conduct of the trial.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Factorial Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: High Intensity Interval
Walking on a treadmill 4min at 80-90% peak heart rate and recovery 4 min at 65% peak heart rate until expenditure of 300 kcal during adaptation (first 4 weeks) and 500 kcal after week number 4 until the end of training.
Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
Active Comparator: Resistance training
Completing a resistance circuit (including upper and lower muscle groups) as many times as needed according to subject weight until expenditure of 300 kcal during adaptation (first 4 weeks) at 20-30% of 1 one-rep max and 500 kcal after week number 4 until the end of training, at 40-60% of one-rep max.
Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
Active Comparator: Plus: High Intensity Interval + Resistance Training
Walking on a treadmill as intervention 1 until 50% the energy expenditure prescribed is reached, then completing a resistance circuit until 100% energy expenditure is reached. Exercise will be performed at three sessions per week.
Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
Placebo Comparator: Usual clinical care
This group will receive the usual clinical care according to the consensus recommendations of the national goals for cardiovascular health promotion and disease reduction of the American Heart Association and Colombian guidelines COLDEPORTES.
Dietary restriction (1300-1500kcal) 50-52% carbohydrates, 33-35% fat, 15-20% protein

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change from Baseline in endothelial function as measured by flow-mediated vasodilation (FMD)
Time Frame: Baseline and 12 weeks immediately after the interventions ends
FMD will be measured using the guidelines reported by Corretti et al. The diameter of the brachial artery will be assessed using a high-resolution ultrasound device (Siemens SG-60, USA), equipped with a 7.5 MHz linear array transducer.
Baseline and 12 weeks immediately after the interventions ends

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change from Baseline in body Composition as measured by Dual Energy X-ray Absorptiometry
Time Frame: Baseline and 12 weeks immediately after the interventions ends
Changes in abdominal and total adiposity (DEXA), lean tissue mass and bone mass (DEXA) the 12 weeks intervention program
Baseline and 12 weeks immediately after the interventions ends
Body Weight
Time Frame: Baseline and 12 weeks immediately after the interventions ends
Baseline and 12 weeks immediately after the interventions ends
Body Mass Index
Time Frame: Baseline and 12 weeks immediately after the interventions ends
BMI will be calculated as the body weight in kilograms divided by the square of the height in meters.
Baseline and 12 weeks immediately after the interventions ends
Blood Pressure
Time Frame: Baseline and 12 weeks immediately after the interventions ends
Baseline and 12 weeks immediately after the interventions ends
Change from Baseline in peak uptake of volume of oxygen
Time Frame: Baseline and 12 weeks immediately after the interventions ends
It will be determined using a maximum treadmill exercise test (Precor TRM 885, Italy) following the modified Balke protocol
Baseline and 12 weeks immediately after the interventions ends
Change from Baseline in muscular fitness
Time Frame: Baseline and 12 weeks immediately after the interventions ends
Muscular fitness (MF) will be assessed using handgrip test (maximum handgrip strength assessment) using a standard adjustable handle analogue handgrip dynamometer T-18 TKK SMEDLY III®
Baseline and 12 weeks immediately after the interventions ends
Change from Baseline in Flexibility using the sit and reach test
Time Frame: Baseline and 12 weeks immediately after the interventions ends
Baseline and 12 weeks immediately after the interventions ends
Change from Baseline in LDL Cholesterol
Time Frame: Baseline and 12 weeks immediately after the interventions ends
Baseline and 12 weeks immediately after the interventions ends
Change from Baseline in HDL Cholesterol
Time Frame: Baseline and 12 weeks immediately after the interventions ends
Baseline and 12 weeks immediately after the interventions ends
Change from Baseline in Triglycerides
Time Frame: Baseline and 12 weeks immediately after the interventions ends
Baseline and 12 weeks immediately after the interventions ends
Change from Baseline in Glucose
Time Frame: Baseline and 12 weeks immediately after the interventions ends
Baseline and 12 weeks immediately after the interventions ends
Change from Baseline in Hemoglobin A1c
Time Frame: Baseline and 12 weeks immediately after the interventions ends
Baseline and 12 weeks immediately after the interventions ends
Change from Baseline in Quality & satisfaction with life by SF Community - short-form survey (SF-12™) Colombian version
Time Frame: Baseline and 12 weeks immediately after the interventions ends
Baseline and 12 weeks immediately after the interventions ends
Change from Baseline in Heart rate variability
Time Frame: Baseline and 12 weeks immediately after the interventions ends
HRV will be performed according to current recommendations by European Society of Cardiology using an evaluated share-ware
Baseline and 12 weeks immediately after the interventions ends
24-hour dietary recall
Time Frame: Baseline and 12 weeks immediately after the interventions ends
Dietary data will be collected from participants on 24h of their study enrollment. Prior to administration of the 24HR, each subject received two-dimensional food models with depiction of foods and serving sizes in order to assist in reporting portion sizes of food intake.
Baseline and 12 weeks immediately after the interventions ends
Aortic pulse wave velocity (PWVao) and augmentation index (AIx)
Time Frame: Baseline and 12 weeks immediately after the interventions ends
PWVao and AIx will be measured with oscillometric method using the occlusion technique.
Baseline and 12 weeks immediately after the interventions ends

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Robinson Ramírez Vélez, Ph.D, Universidad del Rosario

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2016

Primary Completion (Actual)

December 1, 2016

Study Completion (Actual)

January 1, 2017

Study Registration Dates

First Submitted

March 8, 2016

First Submitted That Met QC Criteria

March 16, 2016

First Posted (Estimate)

March 22, 2016

Study Record Updates

Last Update Posted (Actual)

October 11, 2018

Last Update Submitted That Met QC Criteria

October 10, 2018

Last Verified

October 1, 2018

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 06-1006-2014

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Metabolic Diseases

Clinical Trials on High Intensity Interval

Subscribe